Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017June 12, 2017

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    Phase 3 Trial Finds Kevzara Superior to Humira, and Just as Safe, in Treating Rheumatoid Arthritis
    May 10, 2017May 10, 2017

    Phase 3 Trial Finds Kevzara Superior to Humira, and Just as Safe, in Treating Rheumatoid Arthritis

    News, rheumatoid arthritis
    The drug Kevzara (sarilumab) is more effective than Humira (adalimumab) — and just as safe — in treating rheumatoid arthritis (RA) in patients who cannot tolerate or don’t respond to ... Read more
    Despite Treatment, 80% of RA Patients Report ‘Life-Altering’ Pain Weekly or Even Daily, Survey Finds
    May 8, 2017May 10, 2017

    Despite Treatment, 80% of RA Patients Report ‘Life-Altering’ Pain Weekly or Even Daily, Survey Finds

    News
    Honestly RA, an online survey for Americans with rheumatoid arthritis (RA), found that although most RA patients agree that the treatments improve their lives, 80 percent still experience life-altering pain multiple times ... Read more
    Kevzara Takes Step Toward EU Approval, While FDA Decision Is Expected in May
    May 5, 2017May 5, 2017

    Kevzara Takes Step Toward EU Approval, While FDA Decision Is Expected in May

    News, rheumatoid arthritis
    Kevzara (sarilumab) has received a thumbs-up from the European Medicine Agency (EMA), which has recommended that the European Commission approve it to treat adults with moderate to severe rheumatoid arthritis, according ... Read more
    Rheumatoid Arthritis Patients More Likely to Develop Atherosclerosis, British Study Shows
    May 3, 2017May 3, 2017

    Rheumatoid Arthritis Patients More Likely to Develop Atherosclerosis, British Study Shows

    News, rheumatoid arthritis
    People with rheumatoid arthritis (RA) are more likely to develop atherosclerosis, a chronic inflammatory condition affecting the heart, according to new research. The study, “Imaging atherosclerosis in rheumatoid arthritis: evidence for ... Read more
    Phase 3 Trial of Can-Fite’s Piclidenoson for Treating RA Is Underway
    April 28, 2017April 28, 2017

    Phase 3 Trial of Can-Fite’s Piclidenoson for Treating RA Is Underway

    News
    Can-Fite BioPharma’s Phase 3 ACRobat clinical trial protocol was approved by Barzilai Medical Center’s Institutional Review Board (IRB) and patient enrollment is now ready to begin. The study will be ... Read more
    Researchers Find 2 Potential Molecules for Fighting Rheumatoid Arthritis, Other Inflammatory Diseases
    April 26, 2017April 26, 2017

    Researchers Find 2 Potential Molecules for Fighting Rheumatoid Arthritis, Other Inflammatory Diseases

    News, rheumatoid arthritis
    Greek researchers have found two molecules — T23 and T8 — that show promise in treating rheumatoid arthritis and other chronic inflammatory diseases. Both molecules act against tumor necrosis factor ... Read more
    Early Treatment Improves Rheumatoid Arthritis Symptoms, Helps Patients Live Longer, Study Suggests
    April 24, 2017April 24, 2017

    Early Treatment Improves Rheumatoid Arthritis Symptoms, Helps Patients Live Longer, Study Suggests

    News, rheumatoid arthritis
    Earlier and more aggressive treatment of rheumatoid arthritis (RA) helps patients grip things, walk and dress themselves better — and live longer, a study suggests. The daily lives of people ... Read more
    Inmedix, Omegawave to Adapt Elite-athlete Tests to Rheumatoid Arthritis Diagnosis
    April 19, 2017April 19, 2017

    Inmedix, Omegawave to Adapt Elite-athlete Tests to Rheumatoid Arthritis Diagnosis

    News, rheumatoid arthritis
    Inmedix and Omegawave will work together on medical applications of tests related to athletes’ performance, with one target being rheumatoid arthritis (RA). A key goal will be to enhance biomarker evaluation ... Read more
    FDA Asks More Information a Second Time on Baricitinib as Arthritis Therapy
    April 17, 2017April 19, 2017

    FDA Asks More Information a Second Time on Baricitinib as Arthritis Therapy

    News, rheumatoid arthritis
    U.S. regulators want additional dosing- and safety-related information before they will approve Eli Lilly and Incyte‘s New Drug Application (NDA) request for the rheumatoid arthritis (RA) treatment baricitinib. It is the second ... Read more
    Obesity May Alter Diagnosis, Management of RA When Blood Tests Are Used
    April 12, 2017April 12, 2017

    Obesity May Alter Diagnosis, Management of RA When Blood Tests Are Used

    News, rheumatoid arthritis
    Obesity in women may interfere with the diagnosis and monitoring of rheumatoid arthritis (RA) through blood tests, according to a new study. Researchers call for more attention to the obesity ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required

    Rheumatoid Arthritis News

    BioNews Services, LLC
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2021 All rights reserved.
      We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more